MBOT Stock Gains Following FDA Submission of the LIBERTY System

Microbot Medical Inc. (MBOT) recently announced that it has submitted a 510(k) premarket notification to the FDA for its LIBERTY system. The 510(k) submission follows the successful completion of its multi-center, single-arm trial to evaluate the performance and safety of LIBERTY in human subjects undergoing Peripheral Vascular Interventions.The company anticipates FDA marketing clearance during the second quarter of 2025, with U.S. commercialization activities expected to commence after the clearance.Likel ...